• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Inspire Medical Systems, Inc. Announces Preliminary Results for Second Quarter of 2024 and Updates 2024 Revenue Outlook

    7/29/24 6:45:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care
    Get the next $INSP alert in real time by email

    MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced certain preliminary, unaudited results for the quarter ended June 30, 2024, and updated full year 2024 revenue outlook. The company plans to report its complete results and host its earnings conference call for the second quarter of 2024 on August 6, 2024.

    Preliminary, Unaudited Second Quarter Revenue

    • Revenue for the second quarter is anticipated to be $195.9 million, a 30% increase over the same quarter of 2023
      • U.S. revenue is expected to be $187.8 million, a 30% increase over the same quarter of 2023
      • Revenue outside of the U.S. is expected to be $8.1 million, a 27% increase over the same quarter of 2023

    Updated Full Year 2024 Revenue Guidance

    • Revenue for full year 2024 is anticipated to be in the range of $788 million to $798 million, which represents growth of 26% to 28% over full year 2023. This represents a $13 million increase over initial 2024 revenue guidance range of $775 million to $785 million.

    "We are so proud of our team's strong execution and revenue performance in the second quarter, which showed sequential revenue growth acceleration in the U.S.," said Tim Herbert, Chairman and CEO of Inspire. "With the strong momentum we are seeing in our business, we have increased confidence regarding strong continued revenue growth in the second half of 2024. As a result, we are increasing our revenue guidance to $788 million to $798 million for full year 2024. We look forward to reporting full results on August 6th," concluded Tim Herbert.

    About Inspire Medical Systems

    Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR and PDMA-approved neurostimulation technology of its kind that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

    For additional information about Inspire, please visit www.inspiresleep.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding our preliminary, unaudited second quarter revenue results, and our expectations regarding full year 2024 revenue outlook.   In some cases, you can identify forward-looking statements by terms such as ‘‘may,'' ‘‘will,'' ‘‘should,'' ‘‘expect,'' ‘‘plan,'' ‘‘anticipate,'' ‘‘could,'' "future," "outlook," "guidance," ‘‘intend,'' ‘‘target,'' ‘‘project,'' ‘‘contemplate,'' ‘‘believe,'' ‘‘estimate,'' ‘‘predict,'' ‘‘potential,'' ‘‘continue,'' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

    These forward-looking statements are based on management's current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, estimates regarding the annual total addressable market for our Inspire therapy in the U.S. and our market opportunity outside the U.S.; future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; commercial success and market acceptance of our Inspire therapy; the impact of macroeconomic trends; general and international economic, political, and other risks, including currency, inflation, stock market fluctuations and the uncertain economic environment; our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize; competitive companies and technologies in our industry; our ability to enhance our Inspire system, expand our indications and develop and commercialize additional products; our business model and strategic plans for our products, technologies and business, including our implementation thereof; our ability to accurately forecast customer demand for our Inspire system and manage our inventory; our dependence on third-party suppliers, contract manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand, manage and maintain our direct sales and marketing organization, and to market and sell our Inspire system in markets outside of the U.S.; risks associated with international operations; our ability to manage our growth; our ability to increase the number of active medical centers implanting Inspire therapy; our ability to hire and retain our senior management and other highly qualified personnel; risk of product liability claims; risks related to information technology and cybersecurity; risk of damage to or interruptions at our facilities; our ability to commercialize or obtain regulatory approvals for our Inspire therapy and system, including our next generation Inspire therapy system, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the U.S. and international markets; and the timing or likelihood of regulatory filings and approvals. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as updated in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 to be filed with the SEC, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.

    Investor and Media Contact

    Ezgi Yagci

    Vice President, Investor Relations

    [email protected]

    617-549-2443



    Primary Logo

    Get the next $INSP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INSP

    DatePrice TargetRatingAnalyst
    11/20/2024$220.00 → $255.00Neutral → Buy
    BofA Securities
    5/8/2024$265.00 → $225.00Buy → Neutral
    BofA Securities
    4/19/2024$285.00Outperform
    RBC Capital Mkts
    3/19/2024$250.00Overweight
    Morgan Stanley
    2/6/2024$278.00Overweight
    KeyBanc Capital Markets
    1/19/2024$245.00Buy
    Jefferies
    1/2/2024$210.00Buy → Hold
    Stifel
    12/13/2023$245.00 → $187.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $INSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mccormick Shawn exercised 4,000 shares at a strike of $16.00, increasing direct ownership by 17% to 28,046 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      6/6/25 6:06:02 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Officer Rondoni John sold $259,025 worth of shares (1,734 units at $149.38), decreasing direct ownership by 11% to 13,766 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      5/21/25 4:05:14 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Director Ellis Gary Lee was granted 1,266 shares, increasing direct ownership by 28% to 5,861 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      5/5/25 8:26:47 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sparks Charisse Y bought $15,350 worth of shares (100 units at $153.50), increasing direct ownership by 11% to 998 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      1/24/24 4:32:03 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    SEC Filings

    See more
    • Inspire Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)

      6/13/25 6:19:04 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Inspire Medical Systems Inc.

      SD - Inspire Medical Systems, Inc. (0001609550) (Filer)

      5/30/25 4:12:28 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Inspire Medical Systems Inc.

      144 - Inspire Medical Systems, Inc. (0001609550) (Subject)

      5/19/25 4:01:53 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Inspire Medical Systems upgraded by BofA Securities with a new price target

      BofA Securities upgraded Inspire Medical Systems from Neutral to Buy and set a new price target of $255.00 from $220.00 previously

      11/20/24 7:43:58 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems downgraded by BofA Securities with a new price target

      BofA Securities downgraded Inspire Medical Systems from Buy to Neutral and set a new price target of $225.00 from $265.00 previously

      5/8/24 7:48:44 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • RBC Capital Mkts initiated coverage on Inspire Medical Systems with a new price target

      RBC Capital Mkts initiated coverage of Inspire Medical Systems with a rating of Outperform and set a new price target of $285.00

      4/19/24 7:26:47 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 21, 2023 - FDA Roundup: March 21, 2023

      For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

      3/21/23 3:12:46 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inspire Medical Systems, Inc. to Report Second Quarter 2025 Financial Results on August 4, 2025

      MINNEAPOLIS, July 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the second quarter 2025 after the close of trading on Monday, August 4. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followin

      7/7/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. to Present at the Truist Securities MedTech Conference

      MINNEAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025. Inspire is scheduled to present at 11:20 a.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investors.inspiresl

      6/3/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight

      MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investor

      5/30/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Financials

    Live finance-specific insights

    See more
    • Inspire Medical Systems, Inc. to Report Second Quarter 2025 Financial Results on August 4, 2025

      MINNEAPOLIS, July 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the second quarter 2025 after the close of trading on Monday, August 4. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followin

      7/7/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook

      Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2025. Recent Business Highlights Generated revenue of $201.3 million in the first quarter of 2025, a 23% increase over the same quarter last yearAchieved gross margin of 84.7% in the first quarter of 2025Generated earnings per share of $0.10 in

      5/5/25 4:02:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025

      MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the first quarter 2025 after the close of trading on Monday, May 5. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q1 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following l

      4/1/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Leadership Updates

    Live Leadership Updates

    See more
    • Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors

      MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.   "Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, a

      4/21/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Presidio Medical™ Announces Appointment of Richard J. Buchholz to Join its Board of Directors

      Presidio Medical, Inc., a clinical stage company developing a transformational neuromodulation platform, is pleased to announce Richard J. Buchholz will join its Board of Directors. Rick is the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE:INSP), where he has played a pivotal role in driving strategic financial and operational growth for the global leader in the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. "We are excited that Rick is joining the Board of Directors of Presidio Medical at this critical time in our company's journey. His leadership and financial acumen will be instrumental in advanc

      12/5/24 12:12:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

      SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

      11/12/24 10:32:14 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

      SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

      10/4/24 2:09:06 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Inspire Medical Systems Inc. (Amendment)

      SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

      2/13/24 5:06:20 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care